Kailera makes a splash on Nasdaq as anti-obesity drug frenzy continues

Kailera Therapeutics delivered a standout initial public offering on the Nasdaq, with its shares surging 62.5% in early trading. The company raised $625m by offering approximately 39 million shares at $16, the top of its indicative range, before opening at $26. This performance underscores sustained investor appetite for companies positioned in the obesity treatment space, a rapidly expanding market.

This momentum comes amid a broader resurgence in IPO activity following a slowdown triggered by geopolitical tensions and volatility in tech stocks. The biotech sector, which had long been sidelined, could see a renewed boost driven by the prospects of GLP-1 receptor-based therapies. This segment is already attracting numerous players seeking to challenge Eli Lilly and Novo Nordisk in a market projected to reach $150bn annually by the end of the decade.

Kailera is currently developing several drug candidates, including KAI-9531, a weekly injectable targeting GLP-1/GIP receptors now in Phase 3 clinical trials. An oral treatment, KAI-7535, is also under development. Despite the current enthusiasm, short-term prospects remain tied to broader market trends, as major clinical results are not expected until 2028, according to analysts.